EUCTR2017-002676-87-ES进行中（未招募）1 期
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab plus Cisplatin, in Combination with Radiotherapy in Participants with Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,046
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Histologically proven SCCHN from one of the following primary sites: oral cavity, oropharynx, hypopharynx, and larynx
- •Locally advanced disease which is un-resectable, or resectable but suitable for an organ sparing approach
- •No previous radiotherapy or systemic treatment for SCCHN
- •Eastern cooperative oncology group (ECOG) score of 0-1
- •Age > 18 years or age of majority
- •Measurable disease by RECIST 1.1 criteria, and tumor assessment performed prior to randomization
- •Sufficient sample of fresh or archival (< 3 months from informed consent date) formalin-fixed, paraffin-embedded (FFPE) tissue block, or unstained tumor tissue sections, with an associated pathology report, must be submitted for biomarker evaluation for PD-L1 status. Central lab must provide Interactive Response Technology (IRT) with confirmation of receipt of evaluable tumor tissue prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle or aspiration is unacceptable for submission. PD-L1 status must be available prior to randomization.
- •HPV p16 test result available (performed locally or centrally) for participants with oropharyngeal disease
- •Patients must be of intermediate or high risk categories*:
- •High risk:
- •Oral cavity, hypopharynx, larynx, oropharynx (p16 negative): Stage III/ IV
- •Oropharynx (p16 positive): Stage III (T4 any N or T1-3 N3) - irrespective of smoking status.
- •Intermediate risk:
- •Oropharynx (p16 positive): T3 N0-2or T1-3 N2 disease if smoking > 20 pack year history
- •*TNM staging according to AJCC version 8
- •Cohort 1 (cisplatin-ineligible participants) Specific Inclusion Criteria (Arm A and Arm B)
- •Physician assesses participant to be non-eligible for treatment with platinum based combined CRT. This must be for one or more of the following reasons:
- •Age = 70 years at enrolment
- •Creatinine clearance < 60mL/min and > 30mL/min (using the Cockcroft and Gault formula– see below**)
- •Severe hearing loss (minimal hearing threshold of 80 dB or more in either ear)
- •Cohort 2 (cisplatin-eligible participants) Specific Inclusion Criteria (Arm C and Arm D)
- •Adequate renal function within 28 days prior to randomization as follows:
- •Creatinine clearance = 60 mL/min. as determined by 24 hour collection or estimated by Cockcroft-Gault formula:
- •Creatinine Clearance = [(140 - age) x (wt in kg)/Serum Cr mg/dL x 72**
- •**Participants aged = 70 years may enter either Cohort 1 or 2 dependent on whether the physician’s assessment is that
- •the participant is eligible for cisplatin (Cohort 2) or ineligible for cisplatin (Cohort 1) based on their age. It is anticipated that in the majority of cases, patients aged = 70 years will be considered ineligible for cisplatin and enter cohort 1.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 291
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 755
排除标准
- •Carcinoma originating in the nasopharynx or paranasal sinus, squamous cell carcinoma that originated from the skin and salivary gland or non-squamous histology (eg, mucosal melanoma), squamous cell carcinoma of unknown primary
- •Clinical or radiological evidence of metastatic disease
- •Prior radiotherapy that overlaps with radiation fields
- •Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation or study drug administration, impair the ability of the participant to receive protocol therapy, or interfere with the interpretation of study results
- •Active unstable angina and/or congestive heart failure
- •Myocardial infarction within 6 months prior to randomization
- •Participants who have a weight loss of > 10% of body weight between screening and randomization will be removed from the study
- •Participants with an active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- •Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
研究者
相似试验
进行中（未招募）
1 期
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 TreatmentMedDRA version: 20.0Level: LLTClassification code 10001624Term: Alcoholic hepatitisSystem Organ Class: 100000004871Alcoholic hepatitisEUCTR2020-004534-38-DEDURECT Corporation300
进行中（未招募）
不适用
A Clinical Trial Investigating OSI-906 in Patients with Adrenocortical CarcinomaAdrenocortical CarcinomaMedDRA version: 14.1Level: PTClassification code 10001388Term: Adrenocortical carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012820-97-DEAstellas Pharma Global Development, Inc.135
招募中
3 期
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Metastatic Breast CancerBreast carcinoma10006291Breast cancerNL-OMON51870Merck Sharp & Dohme (MSD)24
进行中（未招募）
不适用
A study of AMG 416 in the treatment of secondary hyperparathyroidism in chronic kidney diseaseSecondary hyperparathyroidism in subjects with chronic kidney diseaseMedDRA version: 17.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersMedDRA version: 17.0Level: LLTClassification code 10020706Term: Hyperparathyroidism NOSSystem Organ Class: 10014698 - Endocrine disordersEUCTR2012-002805-23-ATKAI Pharmaceuticals, Inc (a subsidiary of Amgen, Inc.)500
进行中（未招募）
1 期
A phase 3 randomised, double-blind, placebo-controlled efficacy and safety study funded by Furiex Pharmaceuticals. The purpose of this study is to find out if a new investigational drug called JNJ-27018966 is safe and effective as a treatment for diarrhea-predominant Irritable Bowel Syndrome (IBS-d).Diarrhea-predominant irritable bowel syndromeMedDRA version: 20.1 Level: LLT Classification code 10060845 Term: Diarrhea predominant irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 20.1 Level: PT Classification code 10023003 Term: Irritable bowel syndrome System Organ Class: 10017947 - Gastrointestinal disordersEUCTR2012-001600-38-GBFuriex Pharmaceuticals1,282